AnaptysBio, a clinical-stage biotechnology company based in San Diego, focuses on immune cell modulators and has two checkpoint agonists in Phase 2 trials for autoimmune diseases. The company went public on January 26, 2017, and employs 117 staff.
Hollings Renton sold 3,015 shares of ANAB on 18 June at $23.97 per share, worth a total of $72K. They now own 4,965 ANAB shares, or a 38% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
